Hyperkalemia
In hyperkalemia, 13 trials of 5 agents of HIF-PHIs were reported, containing 12,771 participants[2, 12, 16, 27, 28, 30-32, 35, 36, 40, 41]. There was no significant increase in risks with Roxadustat (RR: 1.03, 95% CI: 0.78-1.37, p=0.81, I2=14.7%), Daprodustat (RR: 0.91, 95% CI: 0.63-1.33, p=0.63, I2=14.7%), Desidustat (RR: 5.00, 95% CI: 0.58-43.29, p=0.14, I2=14.7%), Vadadustat (RR: 0.84, 95% CI: 0.60-1.17, p=0.30, I2=14.7%) and Molidustat (RR: 0.37, 95% CI: 0.08-1.67, p=0.20, I2=14.7%) compared with ESAs (Figure 4).